Al­to Neu­ro­science and Fractyl Health add to biotech IPO mo­men­tum in Fri­day dou­ble­head­er

Two more biotechs will go pub­lic Fri­day morn­ing as Al­to Neu­ro­science and Fractyl Health build on the mo­men­tum cre­at­ed by CG On­col­o­gy and Ar­riVent Bio­Phar­ma’s Nas­daq list­ings last week.

Cal­i­for­nia drug­mak­er Al­to Neu­ro­science raised about $128.6 mil­lion in its up­sized NYSE list­ing, as the mid-stage CNS biotech priced at $16 apiece $AN­RO, the high end of the range it pro­posed ear­li­er this week. Fractyl Health, mean­while, land­ed on the Nas­daq with $110 mil­lion in pro­ceeds by pric­ing at $15 a share $GUTS, the mid-point of the range it dis­closed on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER